CTAD: Anti-tau vaccine demonstrated safety, immunogenicity in phase I study

BARCELONA – An investigational anti-tau vaccine has passed its first big clinical milestone with a successful phase I trial of 30 patients with mild to moderate Alzheimer’s disease.

<table...